Title: Quantifying the change of spasticity after intrathecal baclofen administration: A descriptive retrospective analysis
| Autor: | Lisa A. Beck, Matthew J. Pingree, Thomas P. Pittelkow, Daniel R. Lueders, Markus A. Bendel, Bryan C. Hoelzer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Baclofen Post-dural-puncture headache 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 030202 anesthesiology medicine Humans Spasticity Injections Spinal Aged Retrospective Studies business.industry Muscle Relaxants Central Cerebral Palsy General Medicine Perioperative Infusion Pumps Implantable Middle Aged Spinal cord Intrathecal baclofen body regions medicine.anatomical_structure chemistry Muscle Spasticity Anesthesia Surgery Female Neurology (clinical) Implant medicine.symptom business Complication 030217 neurology & neurosurgery |
| Zdroj: | Clinical neurology and neurosurgery. 171 |
| ISSN: | 1872-6968 |
| Popis: | Objectives Exploratory research quantifying the change of spasticity among patients who underwent baclofen intrathecal drug delivery system (IDDS) implantation. Patients and Methods: 88 patients with a baclofen IDDS were identified. Patient characteristics, spasticity scores pre/post intrathecal baclofen test dose, and IDDS perioperative implantation records were collected. The primary outcome was to quantify the extent to which there was a change in Modified Ashworth Scores (MAS) pre/post-intrathecal baclofen test dose administration. Secondary outcomes included the prevalence of perioperative IDDS implantation complications. Results The mean age at IDDS implant was 44.2 years (range, 19–71), and 62.5% were male. 45.5% had spasticity of spinal cord origin, 9% of cerebral origin, and 45.5% of other upper motor neuron dysfunction. Reduction of MAS in the spinal cord origin group was 2.6 (mean, 3.5 to 0.9), cerebral origin group was 2.9 (mean, 3.3 to 0.4), and other origin group was 2.5 (mean, 3.6 to 1.1). In all patients, post dural puncture headache was the most commonly reported complication at 22.7%. Conclusion This report offers novel findings documenting a quantifiable change of at least two points on the MAS before and after intrathecal baclofen test dose as statistically significant and could prove to be useful information to enhance the decision making process to proceed with intrathecal baclofen beyond assessment of functional abilities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect